logo

For the Inventor, By the Inventor

Vienna, Austria

Affiris Ag


USPTO Granted Patents = 25

% Expired Patents = 56.0



Forward Citations = 21

Loading Chart...
Loading Chart...

35 inventors (with patents filed for the assignee):

goldMedal Guenther Staffler (11 out of 12 patents)

silverMedal Markus Mandler (10 out of 12 patents)

bronzeMedal Frank Mattner (9 out of 22 patents)

4.  Sylvia Brunner (8 out of 9 patents)

5.  Claudia Juno (7 out of 8 patents)

6.  Gergana Galabova (6 out of 8 patents)

7.  Gabriele Winsauer (6 out of 7 patents)

8.  Walter G Schmidt (6 out of 23 patents)

9.  Harald Weninger (5 out of 6 patents)

10.  Radmila Santic (5 out of 6 patents)

11.  Achim Schneeberger (4 out of 15 patents)

12.  Erika Bilcikova (4 out of 5 patents)

13.  Pola Linzmayer-Hirt (4 out of 5 patents)

14.  Birgit Schuh (4 out of 5 patents)

15.  Edith Kopinits (4 out of 5 patents)


Core Competencies:
Alpha-Synuclein
Peptide Vaccines
Alzheimer's Disease
Neurodegenerative Disorders
C5a Inhibition
PCSK9
Huntington's Disease
Atherosclerosis
Cholesterol Transport
Beta-Amyloidoses
Amyloidoses
Vaccine Induction

25 patents:

1. 12653872 - MIMOTOPES OF ALPHA-SYNUCLEIN AND VACCINES THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHY (2026-06-16),
2. 11065273 - Treatment and prevention of alzheimer's disease (AD) (2021-07-20),
3. 10933123 - Peptide vaccines usable for hypercholesterolemia related diseases (2021-03-02),
4. 10646565 - Treatment of alzheimer'S disease (AD) with an aluminum salt (2020-05-12),
5. 10576131 - IL-23-p19 vaccines (2020-03-03),
6. 10517935 - Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders (2019-12-31),
7. 10478454 - Treatment of Alzheimer's disease (AD) with aluminum oxyhydroxide (2019-11-19),
8. 10406197 - Substances and methods for the use in prevention and/or treatment in Huntington's disease (2019-09-10),
9. 10344062 - Method of inhibiting C5a (2019-07-09),
10. 10053518 - Substances and methods for the use in prevention and/or treatment in Huntington's disease (2018-08-21),
11. 10004791 - Peptide vaccines against PCSK9 (2018-06-26),
12. 9999659 - Treatments using a peptide and/or vaccine (2018-06-19),
13. 9964547 - Method for detecting aSyn-specific antibodies in a biological sample (2018-05-08),
14. 9724399 - Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders (2017-08-08),
15. 9669079 - PCSK9 peptide combination vaccine and method of use (2017-06-06),
Affiris AG is a biotechnology company based in Vienna, Austria, specializing in the development of innovative peptide-based therapeutics. The company focuses on creating advanced vaccine technologies and therapeutic solutions for various diseases, including autoimmune disorders and infectious diseases. Affiris leverages its proprietary platform to design and manufacture peptide vaccines that aim to enhance immune responses, contributing to the advancement of personalized medicine and improving patient outcomes in the healthcare sector.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Affiris Ag
25 Patents

#39 in Vienna

#143 in Austria

#25,681 in the World

Vienna, AT
Vienna, Austria

Affiris Ag

Forward Citations = 21

35 inventors:

goldMedal Guenther Staffler (11 out of 12 patents)

silverMedal Markus Mandler (10 out of 12 patents)

bronzeMedal Frank Mattner (9 out of 22 patents)

4.  Sylvia Brunner (8 out of 9 patents)

5.  Claudia Juno (7 out of 8 patents)

Please report any incorrect information to [email protected]
Loading…